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Our immune system bears the tremendous task of mounting effective anti-microbial
responses whilst maintaining immunoregulatory functions to avoid autoimmunity. In order
to quickly respond to pathogens, Dendritic cells (DC) are armed with pattern recognition
receptors (PRRs), allowing them to recognize highly conserved pathogen-associated mol-
ecular patterns (PAMPs) that are uniquely expressed by invading microbes. PRR activation
can trigger DCs to release the pleiotropic cytokine, Type I interferons (IFN), which facil-
itates various biological functions in different immune cell types. In this review, we will
discuss the classical PRR-induced Type I IFN response in DCs as well as describe a novel
mechanism for Type I IFN induction by the tumor-necrosis factor receptor superfamily
(TNFRSF) members, TNFR-1 and lymphotoxin-β receptor (LTβR). While PRR activation dur-
ing viral infection, produces large amounts of Type I IFN in a relative short period of time,
TNFRSF-inducedType I IFN expression is modest with gradual kinetics.Type I IFN can exert
pro-inflammatory effects, but in some cases it also facilitates immune-regulatory functions.
Therefore, DCs are important regulators of immune responses by carefully modulatingType
I IFN expression.
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INTRODUCTION
Dendritic cells (DCs) play a critical role in bridging the innate
immune response with the adaptive immune system. DCs reside
throughout the body, particularly enriched in secondary lymphoid
organs (SLOs), intestinal lamina propria, and the epidermal layer
of the skin, and they constantly sample antigen to maintain balance
between immunity and tolerance. Infection triggers pattern recog-
nition receptors (PRR) activation, promoting DC maturation, and
the production of inflammatory cytokines including TNF-α, inter-
leukin (IL)-1, IL-6, IL-12, and Type I interferons (IFN). Upon
activation fully mature DCs migrate to SLOs where they inter-
act with naive T cells, resulting in the activation of the adaptive
immune response. DCs can be broadly categorized into con-
ventional DCs (cDCs) and plasmacytoid DCs (pDCs). cDCs are
comprised of different subsets governed by differential expression
of CD4 and CD8α (Villadangos and Schnorrer, 2007; Hashimoto
et al., 2011). cDCs are highly efficient at presenting external anti-
gens through the major histocompatibility complex (MHC) class
I molecule to CD8+ T cells for the generation of cytotoxic T lym-
phocytes (CTLs), a process known as cross-presentation that plays
an important role in pathological contexts including autoimmune
disease, allograft rejection, and tumor immunity (Carbone and
Bevan, 1990; Den Haan et al., 2000; Pooley et al., 2001). pDCs
are also capable of capturing, processing, and presenting antigens
to T cells (Sapoznikov et al., 2007; Young et al., 2008), but in
comparison to cDCs, they possess more restricted antigen uptake
and lower levels of co-stimulatory molecules and MHC (Colonna
et al., 2004; Dalgaard et al., 2005; Young et al., 2008). Instead, pDCs
patrol between blood vessels and the lymphatic system, and when
they encounter viruses, they are capable of secreting very large
amounts of Type I IFN in a short period of time as a strategy
for viral control (Siegal, 1999; Colonna et al., 2004). Therefore,
together cDCs and pDCs provide both distinct and overlapping
contributions towards host defense against pathogens.
IFNs were first discovered to be an important anti-viral factor
that interferes with viral replication in mammalian cells. There are
three classes of IFN (Type I, II, and III) categorized based on their
structural homology and the specific receptor with which they
associate (Platanias, 2005). The Type I IFN family is very diverse
and includes a single IFN-β member, numerous IFN-α variants
(13 in human and 14 in mouse), and the lesser known IFN-ε, -κ,
-ω, and -δ (Sen, 2001). Despite this diversity, all Type I IFNs bind
exclusively to the interferon-α receptor (IFNAR). Upon receptor
activation, IFNAR1 and IFNAR2 dimerize and phosphorylate the
Janus Kinase family members TYK2 and JAK1. Activated TYK2
and JAK1 phosphorylate STAT1 and STAT2, and together they
bind IRF9 to form a trimeric transcription factor, ISGF3. ISGF3
translocates into the nucleus and interacts with the ISRE elements
to activate IFN-related gene transcription (Platanias, 2005). Type
I IFNs are secreted by various cell types including fibroblasts,
epithelial cells, innate immune cells, and lymphocytes, and they
represent a key initiating factor against viral infections. In this
review, we will describe the conventional mechanism of Type I
IFN production by cDCs, and for brevity will restrict ourselves
to virus infection scenarios. In addition, we will discuss a novel
mechanism of Type I IFN induction that is triggered by tumor-
necrosis factor receptor superfamily (TNFRSF) members such as
TNFR-1 and lymphotoxin-β receptor (LTβR), independent of PRR
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activation. Finally, we will contextualize the versatile role of Type
I IFN in tuning T cell responses in different contexts such as
responses to replicating pathogens as opposed to cell-associated
protein antigens.
PRR-INDUCED TYPE I IFN IN RESPONSE TO VIRAL INFECTION
Our immune system is in a constant evolutionary battle with
pathogens that has played out through millennia. In order to com-
bat viral infections, the immune system relies on detection tools,
in particular PRR, that elicit potent Type I IFN expression.
TOLL-LIKE RECEPTORS
Thus far, 13 mammalian TLRs have been identified (10 in human
and 12 in mice) and each TLR recognizes a specific class of
microbial pathogen-associated molecular patterns (PAMPs) that
triggers distinct responses (Casanova et al., 2011). TLRs belong
to the IL-1 receptor family, and all of them contain a common
cytoplasmic domain referred to as the toll-interleukin-1 receptor
(TIR) domain. Upon activation, the TIR domain recruits TIR-
associated adapter molecules including MyD88, TRIF, TRAM,
and TIRAP that mediate various downstream signaling pathways.
TLRs are mainly expressed in immune cells such as neutrophils,
macrophages, DC, and some lymphocytes, while non-immune
cells such as fibroblasts and intestinal epithelial cells express a more
restricted sets of TLRs (Reynolds et al., 2010; Akira, 2011). The
majority of TLRs are found on the cell membrane with the excep-
tion of TLR3, 7–9, and 11–13, which are expressed within intracel-
lular endosomes. These TLRs are associated with the detection of
viral, bacterial, and parasitic nucleic acids (Meylan and Tschopp,
2006; Stetson and Medzhitov, 2006), and their sub-cellular com-
partmentalization allows the immune system to distinguish self
from non-self antigens (Barton et al., 2006). Under certain cir-
cumstances however,host nucleic acids can be mistaken as non-self
resulting in autoimmune diseases. For example, in the case of sys-
temic lupus erythematosis, complexes of autoreactive antibodies
and host nucleic acids can trigger the activation of endosomal
TLRs in pDCs, resulting in uncontrolled production of Type I IFN
and disease pathology (Elkon and Stone, 2011).
Conventional DCs and pDCs express different sets of TLRs
that facilitate their specialized function. Human pDCs lack TLR3
but express high levels of TLR7, TLR8, and TLR9, and they are
responsible for the production of large amounts of Type I IFN
in response to viral infections (Hornung et al., 2002). The signal-
ing pathway downstream of TLR7, 8, and 9 is mediated through
the key adaptor molecule MyD88 (Takeda and Akira, 2005). Upon
activation, MyD88 recruits IRAK4 and IRAK1 to the receptors,
and through interaction of their death domains, IRAK1 becomes
phosphorylated. Activated IRAK1 further recruits and activates the
constitutively expressed IRF7 in pDC, resulting in the production
of Type I IFN (Coccia et al., 2004; Asselin-Paturel and Trinchieri,
2005; Honda et al., 2005).
In contrast to pDCs, the role of TLR7 and TLR8 in cDCs pre-
dominantly initiates a DC maturation program that leads to the
production of IL-12 rather than Type I IFN (Ito, 2002; Larangé
et al., 2009). Type I IFN production by cDC is primarily triggered
through the activation of TLR3 that recognizes viral-derived dou-
ble stranded RNA and TLR4 that recognizes the gram negative
bacterial cell wall component lipopolysaccharide. TLR3 is the only
TLR that exclusively recruits Trif to mediate signaling, while TLR4
signals through both MyD88 and Trif (Weighardt et al., 2004). Trif
is the key adaptor molecule that mediates Type I IFN expression
downstream of both receptors, and upon activation, Trif binds
the TNF receptor-associated factor 3 (TRAF3) and TRAF6, which
recruits RIP1 that induces NFκB activation. Conversely, TRAF3
becomes polyubiquitinated to the lysine at position 63 of the ubiq-
uitin molecule (K63-linkage). K63-linked TRAF3 is essential for
the recruitment of TBK1, IKKε, and IRF3, ultimately leading to
IRF3 phosphorylation (Oganesyan et al., 2005; Tseng et al., 2010;
Häcker et al., 2011). Phoshporylated IRF3 subsequently homo-
dimerizes and translocates into the nucleus. Together IRF3 and
NFκB form the transcription factors required for the expression
of IFN genes (Figure 1). Taken together, pDCs and cDCs have
unique roles in response to infection. The expression of different
PRRs and differences in the signaling that mediate Type I IFN
production in pDCs versus cDCs conspire to contain infection by
triggering a systemic antiviral state and efficiently priming T cell
activation.
RIG-I OR RIG-I LIKE RECEPTORS
In contrast to TLRs which are primarily expressed on innate
immune cells, RIG-I are ubiquitously expressed in the cytoplasm
of all nucleated cells. Instead of actively sensing viral particles,
RIG-I are triggered when cells become infected. RIG-I and the
RIG-I like receptors, such as the melanoma differentiation antigen
5 (MDA5) belong to a family of DExD/H box RNA helicases. The
N-terminal region of RIG-I is characterized by two caspase recruit-
ment domains (CARD), and the C-terminal region contains RNA
helicase activity (Yoneyama and Fujita, 2009). RIG-I recognizes
double stranded RNA by the RNA helicase domain, and through
a CARD–CARD interaction, RIG-I recruits the CARD-containing
adaptor MAVS (also known as VISA, IPS-1, or CARDIF) to medi-
ate downstream events (Yoneyama and Fujita, 2009). Upon activa-
tion, MAVS localizes on sub-cellular compartments including the
mitochondrial membrane and peroxisomes. Signaling through the
peroxisomal-localized MAVS leads to rapid induction of antiviral
genes but independent of Type I IFN production (Dixit et al.,
2010). In contrast, mitochondrial MAVS produces a slower kinetic
that results in Type I IFN expression. Using the mitochondria
membrane as a scaffold and powered by the mitochondrial mem-
brane potential (Koshiba et al., 2011), MAVS interacts with TRAF3,
TBK1, and IKKε to form a “signalosome” that phosphorylates
IRF3 and IRF7 for Type I IFN production (Kawai et al., 2005;
Seth et al., 2005). In vivo models have shown that RIG-I-deficient
mice, despite having intact TLR signaling, succumb to infection
by vesicular stomatitis virus, Newcastle disease virus, and Sendai
virus (Kato et al., 2005). TLRs and RIG-I signaling complement
each other to provide complete coverage across various types of
viruses, and both detection systems are geared toward rapid pro-
duction of Type I IFN that leads to a systemic antiviral state and
the control of viral infection.
INDUCTION OF TYPE I IFN BY THE TNFR FAMILY
The TNFRSF is a very diverse family of receptors comprising of 29
different family members that provide critical signals regulating
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FIGURE 1 | Induction ofType I IFN by PRR during a viral infection. TLR3, 7,
and 9 are mainly expressed within the endosomes of innate immune cells.
Virus or virus-infected cells are taken up by macrophages or DCs, and the viral
nucleic molecules are exposed upon endosomal acidification. Activation of
TLR7 and 9 requires signaling through MyD88 and recruitment of IRAK4,
IRAK1, and IRF7. IRF7 becomes phosphorylated and translocates into the
nucleus upon dimerization resulting in transcription of Type I IFN genes. TLR3
signals exclusively through Trif which binds TRAF6 and recruits RIP1 for NF-κB
activation. Trif also binds TRAF3 leading to TRAF3 K63-linked ubiquintination,
facilitating the recruitment of TBK1, IKKε and IRF3 for IRF3 phosphorylation.
Phosphorylated IRF3 homo-dimerizes and translocates into the nucleus for
transcription of Type I IFN genes. RIG-I or RIG-I like receptors are expressed in
all nucleated cells, and they recognizes viral RNA found in the cytoplasm.
Upon activation, RIG-I recruits MAVS through the CARD domain interaction,
and, analogous to TRIF, MAVS further binds IKKε, TBK1 and IRF3 to promote
IRF3-activation and Type I IFN expression.
numerous physiological functions including inflammation, lym-
phoid organ development, and adaptive immune responses (Force
et al., 1995; Sarin et al., 1995; Lin and Stavnezer, 1996). More
recently, it has been shown that TNFR-1 and LTβR activation
can trigger Type I IFN expression in macrophages and in cDCs
respectively (Yarilina et al., 2008; Summers-deLuca et al., 2011).
The production of Type I IFN by TNFR family members in the
absence of PRR signaling signifies a novel mechanism of Type I
IFN induction that may be critical during immune responses to
non-replicating antigen such as tumor antigens and self-antigens.
TNFR-1 AND TYPE I IFN
TNF-α was first discovered to be an endotoxin-induced serum
factor that exerts cytotoxic effects against sarcoma cells in mice
(Carswell et al., 1975), and it has since been recognized as a
pleiotropic cytokine that regulates numerous biological functions.
Macrophages are major producers of TNF-α in both acute immune
responses and chronic inflammatory diseases. TNF-α induces
inflammation by affecting many different cell types through-
out the body due to the ubiquitous expression of two distinct
receptors, TNFR-1 and TNFR-2. Most biological functions are
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mediated through TNFR-1, while TNFR-2 has been shown to
potentiate TNFR-1 induced cell death (Li et al., 2002). TNF-α
stimulation in primary human and mouse macrophages induces
the phosphorylation of IRF1 and IRF3 leading to the production
of Type I IFN and the secretion of chemokines, such as CXCL10
and CXCL11 (Yarilina et al., 2008). Activated T cells express the
chemokine receptor CXCR3 that binds to CXCL9, CXCL10, and
CXCL11, resulting in their recruitment into sites of inflamma-
tion, and numerous studies have recognized the critical role of
CXCR3 activating chemokines in various immune responses such
as autoimmune mediated skin inflammation and allograft rejec-
tion that lack overt PRR activation (Flier et al., 2001; Meyer et al.,
2001; Zhao et al., 2002). What is important to note is that the
modest and gradual kinetics of the TNFR-1 induced Type I IFN
response described above contrast with the more rapid and robust
Type I IFN induced by PRR mediated responses such as what
occurs during infection – see Figure 2 (Sakaguchi et al., 2003;
Honda et al., 2005; Seth et al., 2005).
LTβR AND TYPE I IFN
LTβR is expressed on stromal cells, DCs, macrophages, and high
endothelial venules, while the ligand LTαβ is found on lymphoid
tissue inducer cells, B cells and activated T cells. LTβR signaling
in stromal cells is required for the development of SLOs (Murphy
et al., 1998; Mebius, 2003), and it also plays an important role in the
homeostatic maintenance of specific subsets of cDCs in the spleen
(Kabashima et al., 2005; Wang et al., 2005; De Trez et al., 2008).
More recently, our lab as well as others have examined the role of
LTβR in DC: T cell cross-talk (Summers-DeLuca et al., 2007; León
et al., 2012). During an immune response, activated CD4+ helper
T cells up-regulate CD40L and LTαβ which binds to the corre-
sponding receptors CD40 and LTβR respectively on cDCs. Both
CD40 and LTβR signaling provide “help” for cDCs so that they
may optimally cross-present antigen for CD8+ T cell activation.
Using an immunization model of cell-associated protein antigen,
we found that LTβR signaling in cDCs is required for optimal
CD8+ T cell clonal expansion while CD40 signaling was required
FIGURE 2 |Type I IFN promotesT cell priming during viral infection
versus soluble antigens. (A) Viruses can trigger PRR activation on
immature DCs, leading to DC maturation and production of various
pro-inflammatory cytokines and a large quantity of Type I IFN. In this
scenario, DCs are strongly activated, and they are capable of directly
interacting with CD8+T cells for the generation of virus-specific CTLs. In
the case of soluble antigens, DCs are poorly activated due to the
absence of PRR-stimulus. Semi-mature DCs must first interact with
helper CD4+ helper T cells which rapidly up-regulate “help signals”
CD40L and LTαβ upon activation. DC-intrinsic LTβR and CD40 activation
promotes DC maturation, with LTβR signaling producing a modest
amount of Type I IFN for a sustained period that facilitates CD8+T cell
expansion. (B)The differences in kinetics and magnitude of Type I IFN
induced by PRR or TNFSFR are illustrated graphically here.
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for CD8+ T cell effector functions. Since Benedict and colleagues
demonstrated that LTβR signaling could induce Type I IFN in stro-
mal cells, independent of PRR activation (Schneider et al., 2008),
we also explored whether direct LTβR stimulation leads to Type I
IFN induction in DCs. We found that, not unlike the scenario for
TNFR-1, LTβR stimulation induced a modest level of Type I IFN
that gradually increased over time. Furthermore, LTβR signaling
was required for maximal Type I IFN production in the context of
LPS (TLR4) co-stimulation (Summers-deLuca et al., 2011).
Interestingly, the modest level of Type I IFN induced by LTβR
signaling in cDCs was important for optimizing CD8+ T cell
clonal expansion in vitro, since low amounts of exogenous IFN-α
can rescue CD8+ T cell expansion in the absence of LTβR signal-
ing. Hence, Type I IFN produced by LTβR or TNFR-1 may facilitate
optimal T cell recruitment and/or clonal expansion (Figure 2).
Given that some autoimmune diseases are characterized by a“Type
I IFN signature” (Lande et al., 2007; Sozzani et al., 2010; Elkon and
Stone, 2011), it will be of interest to determine the relevancy of
these PRR-independent signals for the induction of Type I IFN in
the context of autoimmunity.
THE MANY ROLES OF TYPE I IFN
Thus far, we have described two very different mechanisms for
Type I IFN induction in DCs and monocytes. PRRs detect viral
nucleic acids, to produce a robust Type I IFN response for viral
clearance, and this is particularly the case for pDCs. Conversely,
TNFRSF (TNFR-I, LTβR) induce a modest but prolonged expres-
sion of Type I IFN that acts in a co-stimulatory manner to
potentiate T cell-mediated immunity (Figure 2B). Therefore, the
difference in level, period, and duration of Type I IFN produced by
DCs likely dictate the pleiotropic effects of this cytokine resulting
in pro-inflammatory or pro-regulatory immune functions.
PRO-INFLAMMATORY FUNCTION OF TYPE I IFN
Type I IFN is generally regarded as a pro-inflammatory cytokine
in numerous immune settings such as autoimmune diseases like
psoriasis and systemic lupus erythematosus (Nestle et al., 2005;
Lande et al., 2007; Elkon and Stone, 2011), allograft rejection in
transplantation (Tovey et al., 1996), and immunity against tumors
(Diamond et al., 2011; Fuertes et al., 2011). Type I IFN has robust
pro-inflammatory effects that can act in both an autocrine and
paracrine manner on immune cells to modulate their functions.
During an immune response with minimal PRR activation, DCs
cannot reach maximal immunogenic status, and Type I IFN over-
comes this hurdle by promoting DC maturation (Le Bon and
Tough, 2008; Longhi et al., 2009; Axtell et al., 2013). IFNAR acti-
vation in DC triggers NFκB and p38 mitogen-activated protein
kinase (MAPK) activation, resulting in the up-regulation of MHC
class I and class II as well as co-stimulatory molecules B7-H1
and B7-H2 (Pollara et al., 2006). In addition, blood circulat-
ing monocytes, when differentiated into DCs in the presence of
Type I IFN, upregulate the chemokine receptor CCR7 thus allow-
ing them to migrate more efficiently into SLOs (Parlato, 2001).
In human CD4+ T cells, Type I IFN can complement IL-12 to
drive TH-1 differentiation, where IFNAR-mediated STAT2 phos-
phorylation recruits and activates STAT4, a transcription factor
that potentiates IL-12R signaling (Farrar et al., 2000; Gautier
et al., 2005). Moreover, Type I IFN signaling through STAT4 has
also been implicated in the induction of IFN-γ in natural killer
cells and T cells, particularly in the absence of STAT1 (Nguyen
et al., 2000). Various studies have reported that Type I IFN acts
as a potent third signal that promotes antigen cross-priming
(Curtsinger et al., 2005; Le Bon et al., 2006; Le Bon and Tough,
2008). IFNAR activation in CD8+ T cell can induce chromatin
remodeling through histone acetelyation, promoting transcrip-
tion of many genes required for clonal expansion and produc-
tion of effector molecules (Agarwal et al., 2009). Lastly, Type I
IFN prolongs the CD8+ T cell expansion phase in response to
cross-presented antigen, and it enhances the responsiveness of
antigen specific CD8+ T cells to IL-2 and IL-15 for increased
survival (Le Bon et al., 2006). Hence, Type I IFN can indepen-
dently act on DCs, CD4+ T cells, and CD8+ T cells through
very different mechanisms that facilitate inflammatory immune
responses.
ANTI-INFLAMMATORY ROLE OF TYPE I IFN
Many experimental and clinical settings use Type I IFN as a treat-
ment to quiet inflammatory conditions, suggesting that Type I IFN
can exert immunoregulatory functions. In particular, IFN-β has
been shown to be an effective therapeutic treatment for collagen-
induced arthritis (Van Holten et al., 2004; Adriaansen et al.,
2006), relapsing-remitting multiple sclerosis (MS) (Weinstock-
Guttman et al., 2008) and autoimmune familial Mediterranean
fever (Tweezer-Zaks et al., 2008; Guarda et al., 2011). The anti-
inflammatory functions of Type I IFN, particularly in MS, have
been characterized by numerous studies, and yet the exact mecha-
nism remains unclear. Blood-derived DCs become activated upon
IFNAR activation, however astrocytes and microglia in the cen-
tral nervous system (CNS) down-regulate MHC-II in response to
Type I IFN (Satoh et al., 1995; Hall et al., 1997). T cell recruitment
into the CNS may require Type I IFN to induce relevant CXCR3
attracting chemokines, however other studies have also showed
that prolonged IFN-β treatment in MS patients down-regulates
the expression of cell adhesion molecules such as VCAM-1 and
ICAM-1 in brain endothelial cells, resulting in reduced immune
cell infiltration into the CNS (Corsini et al., 1997; Defazio et al.,
2000). In addition, IFN-β can prevent leukocyte egress from lymph
nodes by down-regulating the sphingosine 1-phosphate receptor-
1 (S1P1) (Shiow et al., 2006; Gao et al., 2009), and S1P receptor
agonists are used to treat MS (Kataoka et al., 2005; Chun and Har-
tung, 2010; Choi et al., 2011; Galicia-Rosas et al., 2012). IFN-β or
IFNAR1 deficient mice have been shown to produce an enhanced
number of antigen specific CD8+ T cells when immunized with a
DNA-based vaccine, suggesting that Type I IFN is also required to
control T cell proliferation (Dikopoulos et al., 2005). Recent stud-
ies showed that IFN-induced STAT1 activation negatively regulates
the expression and function of the oncogene c-myc in CD8+ T
cells which is important for homeostatic proliferation (Gil et al.,
2006, 2012). Furthermore, other studies have also shown that
IFNAR or IFN-β deficient mice exhibit lower numbers of IL-10
producing T cells, which may also explain the increased CD8 T cell
expansion in the absence of IFNAR signaling (Dikopoulos et al.,
2005; Bochtler et al., 2008). It is important to point out, however,
that scenarios where IFNAR signaling is completely absent may
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lead to different effects on shaping T cell responses than situa-
tions where the levels/kinetics of Type I IFN production have been
altered.
CONCLUSIONS
Type I IFN is a pleiotropic cytokine that affects many different
cell types with a wide range of effects. The modulation of the
innate and adaptive immune responses relies on a finely tuned
rheostat of Type I IFN production. The amount of IFN produced
through a particular time frame during the course of an immune
reaction will likely dictate very different outcomes. Therefore,
understanding the mechanisms underlying Type I IFN induction
by DCs is crucial for providing future groundwork in developing
therapeutics that quiet autoimmunity or promote pathogen and
tumour clearance.
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